Abstract
Human ghrelin and human motilin, belonging to the ghrelin/motilin-related peptide family, share 36% amino acid sequence identity, while the human ghrelin receptor exhibits a remarkable 50% overall identity with the human motilin receptor. In addition to their structural resemblance, ghrelin and motilin are the only two mammalian hormones known to decrease in the postprandial period. Ghrelin and motilin participate in initiating the migrating motor complex in the stomach, and stimulate gastrointestinal motility, accelerate gastric emptying, and induce “gastric hunger”. In addition to modulating the release of growth hormone and gut motility, ghrelin plays a crucial role in the secretion and protection of the stomach and colon. Ghrelin mimetics and motilin agonists are currently being developed to reverse gastrointestinal hypomotility disorders. With additional appetite-enhancing, adiposity-promoting, and anti-inflammatory effects, ghrelin and rikkunshito (a traditional Japanese herb enhancing acyl ghrelin signaling) are superior to motilin in the treatment of cancerrelated anorexia and cachexia, post-chemotherapy symptoms, rheumatological diseases, age-related frailty, as well as post-operative, septic, and post-burn gut ileus.
Keywords: Adiposity, anorexia, appetite, cachexia, gastrointestinal, ghrelin, ileus, inflammation, motilin, motility.
Current Pharmaceutical Design
Title:Ghrelin and Motilin in the Gastrointestinal System
Volume: 18 Issue: 31
Author(s): Chih-Yen Chen and Chang-Youh Tsai
Affiliation:
Keywords: Adiposity, anorexia, appetite, cachexia, gastrointestinal, ghrelin, ileus, inflammation, motilin, motility.
Abstract: Human ghrelin and human motilin, belonging to the ghrelin/motilin-related peptide family, share 36% amino acid sequence identity, while the human ghrelin receptor exhibits a remarkable 50% overall identity with the human motilin receptor. In addition to their structural resemblance, ghrelin and motilin are the only two mammalian hormones known to decrease in the postprandial period. Ghrelin and motilin participate in initiating the migrating motor complex in the stomach, and stimulate gastrointestinal motility, accelerate gastric emptying, and induce “gastric hunger”. In addition to modulating the release of growth hormone and gut motility, ghrelin plays a crucial role in the secretion and protection of the stomach and colon. Ghrelin mimetics and motilin agonists are currently being developed to reverse gastrointestinal hypomotility disorders. With additional appetite-enhancing, adiposity-promoting, and anti-inflammatory effects, ghrelin and rikkunshito (a traditional Japanese herb enhancing acyl ghrelin signaling) are superior to motilin in the treatment of cancerrelated anorexia and cachexia, post-chemotherapy symptoms, rheumatological diseases, age-related frailty, as well as post-operative, septic, and post-burn gut ileus.
Export Options
About this article
Cite this article as:
Chen Chih-Yen and Tsai Chang-Youh, Ghrelin and Motilin in the Gastrointestinal System, Current Pharmaceutical Design 2012; 18 (31) . https://dx.doi.org/10.2174/138161212803216915
DOI https://dx.doi.org/10.2174/138161212803216915 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Contribution to Alzheimer Disease: Predictors of Rapid Progression
CNS & Neurological Disorders - Drug Targets Markers of Atherosclerotic Disease: What do they Mean? Current Opinion and Future Trends
Current Pharmaceutical Design Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide
Current Drug Metabolism Technological Barriers in the Use of Electrochemical Microsensors and Microbiosensors for in vivo Analysis of Neurological Relevant Substances
Current Neuropharmacology Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry Cardiac SPECT-CT and PET-CT Imaging
Current Medical Imaging Topiramate in the New Generation of Drugs: Efficacy in the Treatment of Alcoholic Patients
Current Pharmaceutical Design Pathogenesis and Immune Status in COVID-19 Pneumonia - A Minireview
Coronaviruses Elevated Heart Rate, A Risk Factor and Risk Marker of Cardiovascular Disease
Current Hypertension Reviews PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design The Neurovascular Unit: Focus on the Regulation of Arterial Smooth Muscle Cells
Current Neurovascular Research Controversies in Glaucoma: Current Medical Treatment and Drug Development
Current Pharmaceutical Design Mesenchymal Stem Cells in Renal Ischemia-Reperfusion Injury: Biological and Therapeutic Perspectives
Current Stem Cell Research & Therapy Assessing Coronary Blood Flow Physiology in the Cardiac Catheterisation Laboratory
Current Cardiology Reviews Post-locoregional Therapy MRI Evaluation of Malignant Liver Lesions
Current Cancer Therapy Reviews Role of Calcitonin Gene-Related Peptide in Gastric Mucosal Defence and Healing
Current Pharmaceutical Design Pharmacological Treatment of Obstructive Sleep Apnea
Current Pharmaceutical Design Determination of Phytochemicals by GC-MS in Two Fractions (17 and 21) of Methanol Extract of Loranthus Micranthus and their Antioxidant and Anti-Inflammatory Activity
The Natural Products Journal Pleiotropic Effects of Statins - Clinical Evidence
Current Pharmaceutical Design Human Papilloma Virus Vaccine Associated Uveitis
Current Drug Safety